Su Dr. ssa Laura Lattanzio
TITOLI DI STUDIO
– Laurea in Biotecnologie chimico-farmaceutiche (2005)
– Laurea magistrale in Biotecnologie molecolari (2007)
– Abilitazione all’esercizio della professione di Biologo (2010), presso l’Università degli Studi di Pavia
– Specialità in Biochimica clinica (2012), presso l’Università degli Studi di Torino.
ESPERIENZA LAVORATIVA
2004 – 2007: ha frequentato il Laboratorio di Farmacologia Sperimentale ed Applicata dell’Università di Pavia e il Laboratorio di Oncologia Molecolare presso l’Istituto per la Ricerca e la Cura del Cancro (IRCC) di Candiolo (TO) per la stesura delle tesi di laurea.
2006: Stage lavorativo presso University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas, USA, nel Laboratorio della dr. Renata Pasqualini
Dal 2007: con borse di studio e contratti a progetto, frequento il Laboratorio di Genetica Oncologica e di Oncologia Translazionale della SC Oncologia dell’ASO S. Croce e Carle di Cuneo in qualità di biologa specializzata, lavorando su progetti di ricerca di Biologia Molecolare ed Epigenetica. Ha un contratto di collaborazione a progetto finanziato dalla ditta farmaceutica Novartis tramite la Fondazione ARCO-Ricerca Clinica Oncologica-Onlus Cuneo presso lo stesso Laboratorio di Genetica oncologica e di Oncologia Translazionale, per svolgere attività di ricerca sul progetto “Combination of phophatidylinositol-3-kinase targeting and radiotherapy: a preclinical study on an orthotopic xenograft model of head and neck cancer”, in collaborazione con il Centro Antoine Lacassagne di Nizza del dr. Gerard Milano.
Dal 2009: Attività didattica presso il Corso di Laurea per tecnico di Laboratorio Biomedico di Cuneo, Università degli studi di Torino e anche presso Istituti di Istruzione Superiore.
E’ autrice di 25 pubblicazioni su riviste internazionali e partecipa a congressi nazionali ed internazionali. Ha esperienza pluriennale nella conduzione di sperimentazioni cliniche controllate secondo le Norme di Buona Pratica Clinica (GCP).
Vivenza D, Lo Nigro C, Denaro N, Fortunato M, Monteverde M, Tonissi F, Lattanzio L, Astesana V, Gloghini A, Volpi CC, Russi E, Merlano MC.
Int J Biol Markers. 2016 Mar 22:0. doi: 10.5301/jbm.5000193. [Epub ahead of print]
Lattanzio L, Milano G, Monteverde M, Tonissi F, Vivenza D, Merlano M, Lo Nigro C.
Anticancer Drugs. 2016 Mar 15. [Epub ahead of print]
“The effect of Paclitaxel and Nab-Paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines.”
“The effect of Paclitaxel and Nab-Paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines.”
Tonissi F, Lattanzio L, Merlano MC, Infante L, Lo Nigro C, Garrone O.
Invest New Drugs 2015 May 7
Lattanzio L, Borgognone M, Mocellini C, Giordano G, Favata E, Fasano G, Vivenza D, Monteverde M, Tonissi F, Ghiglia A., Fillini C, Bernucci C, Merlano M, Lo Nigro C.
MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumour specimens. Int J Biol Markers, 2014 in press. IF (2012): 1.479
Allen M, Luong P, Hudson C, Leyton J, Delage B, Ghazaly E, Cutts R, Yuan M, Syed N, Lo Nigro C, Lattanzio L, Chmielewska-Kassassir M, Tomlinson I, Roylance R, Whitaker HC, Warren AY, Neal D, Freeza C, Beltran L, Chelala C, Jones LJ, Wu BW, Bomalaski JS, Jackson RC, Lu YJ, Crook T, Lemoine NR, Mather S, Foster J, Sosabowski J, Avril N, Li CF, Szlosarek PW.
Prognostic and therapeutic impact of argininosuccinate synthase-1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Res. 2014;74(3):896-907. IF (2012): 7.856
Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, Syed N, Hatzimichael E, Briasoulis E, Merlano M, Evans A, Thompson A, Leigh I, Fleming C, Inman GJ, Proby C, Crook T.
Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Invest Dermatol. 2013;133(5):1278-85. IF (2012): 6.314
Syed N, Langer J, Janczar K, Singh P, Lo Nigro C, Lattanzio L, Coley HM, Hatzimichael E, Bomalaski J, Szlosarek P, Awad M, O’Neil K, Roncaroli F, Crook T.
Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death Dis. 2013;4:e458. IF (2012): 5.333
Lattanzio L, Tonissi F, Monteverde M, Milano G, Merlano M, Lo Nigro C.
Differential molecular mechanism of the docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells. Anti-cancer drugs, 2012;24(2):120-30. IF (2012): 2.407.
Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D, Monteverde M, Merlano M, Papoudou-Bai A, Bai M, Schmid P, Stebbing J, Bower M, Dyer MJ, Karran LE, ElguetaKarstegl C, Farrell PJ, Thompson A, Briasoulis E, Crook T.
The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma. Br J Cancer. 2012; 107(8):1423-32. IF (2012): 5.042
Palmieri C, Monteverde M, Lattanzio L, Gojis O, Rudraraju B, Fortunato M, Syed N, Thompson A, Garrone O, Merlano M, Lo Nigro C, Crook T.
Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse. Br J Cancer. 2012;107(4):732-8. IF (2012): 5.042
Guérin O, Etienne-Grimaldi MC, Monteverde M, Sudaka A, Brunstein MC, Formento P, Lattanzio L, Maffi M, Tonissi F, Ortholan C, Pagès G, Fischel JL, Lo Nigro C, Merlano M, Milano G.
Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines. Urol Oncol. 2013 Nov;31(8):1567-75. IF (2012): 3.216
Sudaka A, Susini A, Lo Nigro C, Fischel JL, Toussan N, Formento P, Tonissi F, Lattanzio L, Russi E, Etienne-Grimaldi MC, Merlano M, Milano G.
Combination of bevacizumab with irradiation on uveal melanoma: an in vitro and in vivo preclinical study. Invest New Drugs, 2013; 31(1):59-65. IF (2012): 3.357
Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, Syed N, McHugh A, Wang H, Proby C, Garrone O, Merlano M, Hatzimichael E, Briasoulis E, Gojis O, Palmieri C, Jordan L, Quinlan P, Thompson A, Crook T.
NT5E CpG island methylation is a favourable breast cancer biomarker. Br J Cancer. 2012;107(1):75-83. IF (2012): 5.042
Palmieri C, Rudraraju B, Monteverde M, Lattanzio L, Gojis O, Brizio R, Garrone O, Merlano M, Syed N, Lo Nigro C, Crook T.
Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas. Br J Cancer. 2012;107(2):375-81. IF (2012): 5.042
Wang H, Lee S, Lo Nigro C, Lattanzio L, Merlano M, Monteverde M, Matin R, Purdie K, Mladkova N, Bergamaschi D, Harwood C, Syed N, Szlosarek P, Briasoulis E, McHugh A, Thompson A, Evans A, Leigh I, Fleming C, Inman GJ, Hatzimichael E, Proby C, Crook T.
NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br J Cancer. 2012;106:1446-52. IF (2012): 5.042
Vivenza D, Gasco M, Monteverde M, Lattanzio L, Syed N, Colantonio I, Denaro N, Natoli G, Comino A, Russi E, Merlano M, Crook T, Lo Nigro C.
MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer. Oral Oncol, 2012;48(7):602-7. IF (2012): 2.857
Hatzimichael E, Dasoula A, Lo Nigro C, Lattanzio L, Dranitsaris G, Briasoulis E, Crook T.
Bcl2-Interacting Killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications. Leuk Lymphoma, 2012;53(9):1709-13. IF (2012): 2.58
Lo Nigro C, Vivenza, Monteverde M, Lattanzio L, Gojis O, Garrone O, Comino A, Merlano M, Quinlan P, Syed N, Roncarolli F, Shousha S, Purdie CA, Thompson A, Palmieri C, Crook T.
High frequency of complex p53 mutations in CNS metastases from breast cance”, Br J Cancer, 2012;106:397-404. IF (2012): 5.042
Lo Nigro C, Monteverde M, Riba M, Lattanzio L, Tornissi F, Garrone O, Heouaine A, Gallo F, Ceppi M, Borghi F, Comino A, Merlano M.
Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer, Int J Oncol, 2010;37:1219-1228. IF (2012): 2.399
Hannigan A, Smith P, Kalna G, Lo Nigro C, Orange C, O’Brien DI, Shah R, Syed N, Spender LC, Herrera B, Thurlow JK, Lattanzio L, Monteverde M, Maurer ME, Buffa FM, Mann J, Chu DC, West CM, Patridge M, Oien KA, Cooper JA, Frame MC, Harris AL, Hiller L, Nicholson LJ, Gasco M, Crook T, Inman GJ.
Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. J Clin Invest, 2010;120(8):2842-57. IF (2012): 13.069
Stein T, Cosimo E, Yu X, Smith PR, Simon R, Cottrell L, Pringle MA, Bell AK, Lattanzio L, Sauter G, Lo Nigro C, Crook T, Machesky LM, Gusterson BA.
Loss of Reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. Am J Pathol, 2010;177:2323-2333. IF (2012): 4.89
Lo Nigro C, Maffi M, Fischel JL, Monteverde M, Catarsi P, Tonissi F, Lattanzio L, Riba M, Formento P, Milano G, Merlano M.
Impact of erythropoietin on the effects of irradiation under hypoxia, J Cancer Res Clin Oncol. 2009;135(11):1615-23. IF (2012): 2.558